Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
NASDAQ
$23.78
▼ DOWN 4.38% (-1.09)

KEY STATISTICS

Market Cap$2.97 B
52w High$31.77
52w Low$15.13
Dividend Yield—
Frequency—
P/E113.24
Volume1.54M
Shares Out.125.08M

COMPANY

LEADERSHIP

Todd Franklin Watanabe
CHIEF EXECUTIVE
Todd Franklin Watanabe

COMPENSATION 2026

Salary$713,333
Stock Awards$2,067,190
Incentive Plan Pay$579,584
All Other Comp.$14,000
Total$7,223,065

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 31, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
354

PRICE TARGET

Target High$38.00
Target Low$38.00
Target Median$38.00
Target Consensus$38.00

UPCOMING EARNINGS

DateOct 27, 2026
DayTuesday
Rev. Est.$141.02M
OCT
27
TUE

PRICE

$23.78 ▼ DOWN 4.38% (−$1.09)
$23.70$24.00$24.30$24.609:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM23.78

About Arcutis Biotherapeutics, Inc.

https://www.arcutis.com ↗

Arcutis Biotherapeutics develops topical treatments for dermatological conditions, with lead candidate ARQ-151 in Phase III trials for psoriasis and atopic dermatitis, and additional products targeting seborrheic dermatitis, vitiligo, alopecia, an...

INDUSTRY

Biotechnology

A PRODUCT ARCUTIS BIOTHERAPEUTICS, INC. IS KNOWN FOR

ZORYVE (roflumilast) cream 0.05%
ZORYVE (roflumilast) cream 0.05%

ZORYVE (roflumilast) cream 0.05% is a steroid-free topical treatment for mild to moderate atopic dermatitis in children aged 2-5, recently FDA-approved in October 2025, expanding Arcutis Biotherapeutics' ZORYVE franchise in dermatology.

COMPETITORS

COMPETITOR
AMGN COMPARE
INCY COMPARE
LLY COMPARE
PFE COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2022Q4-2022Q3-2023Q4-2023
Product$725K $2.96M ▲$8.11M ▲$21.08M ▲
Other Revenue— — $30M $420K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
142
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.00% · 3.6M
XBI
0.65% · 3.1M
XSU.TO
0.09% · 2.9M
SCHA
0.06% · 540.4K
FESM
0.13% · 336.4K
DX2D.DE
2.17% · 293.9K
PSC
0.22% · 245.5K
FYC
0.37% · 213.2K
PTH
1.29% · 146.2K
NUSC
0.20% · 118.9K
LABU
0.44% · 112.6K
GSSC
0.20% · 87.3K
FSCC
0.66% · 86.7K
BBP
1.25% · 60.1K
RSSL
0.09% · 54.6K
FSML
0.82% · 49.6K
BBSC
0.10% · 31.0K
ISMD
0.19% · 26.4K
ETHO
0.29% · 23.7K
RTWP.L
0.12% · 10.9K
ACSG
0.41% · 8.5K
AFSC
1.96% · 8.0K
ADDS
2.07% · 6.0K
URTY
0.03% · 4.6K
BKSE
0.11% · 4.1K
RFLR
0.10% · 4.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
77.94%
HOLDERS
369
TOP 12 OF 369 · RANKED BY POSITION SIZE
Suvretta Capital Management, LLC
12.4M sh · $326.1M
Jennison Associates LLC
12.3M sh · $230.99M
Rubric Capital Management LP
10.7M sh · $202.63M
Blackrock, Inc.
10.5M sh · $276.5M
Frazier Life Sciences Management, L.P.
9.9M sh · $186.13M
Blackrock Inc.
8.6M sh · $80.19M
Vanguard Group Inc
7.3M sh · $210.65M
Polar Capital Holdings Plc
6.6M sh · $173.23M
State Street Corp
6.3M sh · $148.34M
Gilder Gagnon Howe & Co LLC
4.5M sh · $129.34M
Morgan Stanley
4.5M sh · $116.71M
D. E. Shaw & Co., Inc.
3.9M sh · $103.56M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity4
Return On Assets4
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-05-29
 Josh Gottheimer
Josh Gottheimer
Sale
2023-09-15

INSIDER TRADES

★
DIRECTOR
Curran Terrie
Purchase · 27.1K shares
2026-08-27
★
DIRECTOR
Curran Terrie
Purchase · 11.1K shares
2026-08-27
★
DIRECTOR
Curran Terrie
Sale · 27.1K shares
2026-08-27
★
DIRECTOR
Curran Terrie
Sale · 11.1K shares
2026-08-27

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 1
OUTPERFORM 1
NEUTRAL 1
7 GRADES IN THE LAST 12 MONTHS
Morgan Stanley OVERWEIGHT Guggenheim BUY Needham BUY Mizuho OUTPERFORM TD Cowen BUY HC Wainwright & Co. BUY Goldman Sachs NEUTRAL

SECTORS PEERS

PEERPRICE
CGON$74.34COMPARE
TVTX$65.67COMPARE
XENE$59.99COMPARE
CELC$88.44COMPARE
LEGN$19.88COMPARE
TARS$71.76COMPARE
IRON$80.03COMPARE
ZLAB$26.08COMPARE